ArticleClinical and translational science2022
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
Article in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Depression and Opioid Pragmatic Trial in Pharmacogenetics
A Depression and Opioid Pragmatic Trial in Pharmacogenetics
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Pharmacogenomic-guided opioid therapy for pain: a systematic review and meta-analysis of randomised controlled trials.The pharmacogenomics journal · 2025Pooled it
- Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.JAMA network open · 2026Trial
- CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial.JAMA network open · 2026Trial
- The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.The pharmacogenomics journal · 2023Trial
- Tramadol Co-Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control.Clinical pharmacology and therapeutics · 2026Article
- Leveraging PCORnet® to Advance Clinical Genetics and the Genomic Learning Health System.Medical care · 2026Article
- CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone.Frontiers in pharmacology · 2026Article
- Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025Review
- Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned.Clinical pharmacology and therapeutics · 2024Article
- Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.Clinical and translational science · 2024Article
- Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression.Clinical and translational science · 2024Article
- Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of PreemptiveJournal of pain research · 2024Article
- Precision Medicine in Oral Health and Diseases: A Systematic Review.Journal of personalized medicine · 2023Review
- CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022Review
- Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.Clinical and translational science · 2022Article
- Assessing patient understanding of pharmacogenomic test results: a qualitative study.PharmacogenomicsArticle
- From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's Health.PharmacogenomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 13 institutions in 1 country.
Funding
Abstract
Opioid prescribing for postoperative pain management is challenging because of inter-patient variability in opioid response and concern about opioid addiction. Tramadol, hydrocodone, and codeine depend on the cytochrome P450 2D6 (CYP2D6) enzyme for formation of highly potent metabolites. Individuals with reduced or absent CYP2D6 activity (i.e., intermediate metabolizers [IMs] or poor metabolizers [PMs], respectively) have lower concentrations of potent opioid metabolites and potentially inadequate pain control. The primary objective of this prospective, multicenter, randomized pragmatic trial is to determine the effect of postoperative CYP2D6-guided opioid prescribing on pain control and opioid usage. Up to 2020 participants, age ≥8 years, scheduled to undergo a surgical procedure will be enrolled and randomized to immediate pharmacogenetic testing with clinical decision support (CDS) for CYP2D6 phenotype-guided postoperative pain management (intervention arm) or delayed testing without CDS (control arm). CDS is provided through medical record alerts and/or a pharmacist consult note. For IMs and PM in the intervention arm, CDS includes recommendations to avoid hydrocodone, tramadol, and codeine. Patient-reported pain-related outcomes are collected 10 days and 1, 3, and 6 months after surgery. The primary outcome, a composite of pain intensity and opioid usage at 10 days postsurgery, will be compared in the subgroup of IMs and PMs in the intervention (n = 152) versus the control (n = 152) arm. Secondary end points include prescription pain medication misuse scores and opioid persistence at 6 months. This trial will provide data on the clinical utility of CYP2D6 phenotype-guided opioid selection for improving postoperative pain control and reducing opioid-related risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.